Famitinib

Generic Name: Famitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇FN_₄O_₂

CAS Number: 1044040-56-3

Unique Ingredient Identifier: 768FW21J3L

Background: Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with

51 patients received SHR-1701 and famitinib; 45 were assessable for response, with 7 (28%) in BTC and 3 (15%) in PDAC achieving objective response. Median PFS was 5.1 months for BTC and 2.1 months for PDAC; median OS was 16.0 months for BTC and 5.3 months for PDAC. Safety analysis showed 88.2% experienced TRAEs, with 29.4% grade 3-4 events. Immune/metabolism score predicted response, with responders showing higher immune cell infiltration and lower metabolic activity.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy